Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06798558 · ClinicalTrials.gov registry record · Phase 2
Neoadjuvant Lu-177-PSMA-617 in Patients With High Risk Localized Prostate Cancer Undergoing Radical Prostatectomy
A Phase 2 study of Prostate Adenocarcinoma, sponsored by Hackensack Meridian Health.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 54
- Enrollment target
- 3
- Study locations
NCT06798558 is a Phase 2 study of Prostate Adenocarcinoma that is actively recruiting participants, run by Hackensack Meridian Health. The registered enrollment target is 54 participants, below the 218-participant average among 99 other Prostate Adenocarcinoma trials with a reported enrollment target (75% lower). The trial reports 3 study locations across 2 states.
The verdict
NCT06798558, a Phase 2 study of Prostate Adenocarcinoma, is actively recruiting participants, sponsored by Hackensack Meridian Health.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 54 participants
- Enrollment target
- 3
- Study locations
Study Summary
Male adults with a confirmed diagnosis of prostate adenocarcinoma who meet criteria for localized high risk prostate cancer according to the NCCN guidelines and who are eligible for prostatectomy will be invited to participate. Criteria for high-risk prostate cancer include patients with preoperative prostate biopsy score of Gleason 8 (GS8) (Grade group 4 \[GG4\]) or higher. Patients also need to have a positive PSMA scan on 68-Ga-PSMA-11 PET/CT scan.
Conditions Studied
Interventions
- DRUG Lu-17-PSMA-617
Study Locations (3)
District of Columbia
- MedStar Washington Hospital Center - Washington D.C.
- Lombardi Comprehensive Cancer Center at Georgetown University Medical Center - Washington D.C.
New Jersey
- John Theurer Cancer Center at Hackensack University Medical Center - Hackensack
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 54 participants |
| Start Date | 2025-03-05 |
| Est. Completion | 2029-03 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06798558
The ClinicalTrials.gov registry entry for NCT06798558 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 54 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 218-participant average among 99 other Prostate Adenocarcinoma trials with a reported enrollment target (75% lower). The listed sponsor is Hackensack Meridian Health, which has 90 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Prostate Adenocarcinoma appearing as the primary indexed condition, and to 1 intervention - of which Lu-17-PSMA-617 is the first listed.
NCT06798558 reports 3 study locations spanning 2 distinct geographic areas - top geographies include District of Columbia, New Jersey.
Frequently Asked Questions
What is clinical trial NCT06798558 about?
NCT06798558 is a clinical study titled "Neoadjuvant Lu-177-PSMA-617 in Patients With High Risk Localized Prostate Cancer Undergoing Radical Prostatectomy". Male adults with a confirmed diagnosis of prostate adenocarcinoma who meet criteria for localized high risk prostate cancer according to the NCCN guidelines and who are eligible for prostatectomy will be invited to participate. Criteria for high-risk prostate cancer include patients with preoperativ...
What is the current status of trial NCT06798558?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 54 participants. The study started on 2025-03-05. Estimated completion is 2029-03.
What conditions does trial NCT06798558 study?
This clinical trial studies the following conditions: Prostate Adenocarcinoma.
What interventions are being tested in trial NCT06798558?
The interventions under investigation include: Lu-17-PSMA-617 (DRUG).
Who is sponsoring clinical trial NCT06798558?
This trial is sponsored by Hackensack Meridian Health, which has 90 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06798558 being conducted?
This trial has 3 study locations across District of Columbia, New Jersey. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Prostate Adenocarcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Hyperpolarized Pyruvate (13C) MR Imaging in Monitoring Patients With Prostate Cancer on Active Surveillance
RECRUITING · Phase 2
-
Relugolix and Enzalutamide in Combination With Radiation Therapy for the Treatment of Very High Risk Prostate Cancer, OPTIMAL Trial
RECRUITING · Phase 2
-
Bipolar Androgen Therapy (BAT) and Radium-223 (RAD) in Metastatic Castration-resistant Prostate Cancer (mCRPC)
RECRUITING · Phase 2
-
Intermittent Fasting Using a Fasting-Mimicking Diet to Improve Prostate Cancer Control and Metabolic Outcomes
RECRUITING · Phase 2
-
Extremely Hypofractionated Intensity Modulated Stereotactic Body Radiotherapy for the Treatment of Prostate Cancer With Rising PSA After Radical Prostatectomy
RECRUITING · Phase 2
-
A Study of Enzalutamide Plus the Glucocorticoid Receptor Antagonist Relacorilant Versus Placebo for Patients With High-risk Localized Prostate Cancer
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.